UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1039-1049

2013

Volltextzugriff (PDF)

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Clinical cancer research, 2018-08, Vol.24 (15), p.3528-3538

2018

Volltextzugriff (PDF)

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Cancer, 2020-07, Vol.126 (14), p.3219-3228

2020

Volltextzugriff (PDF)

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1560-1568

2018

Volltextzugriff (PDF)

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.946-963

2016

Volltextzugriff (PDF)

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.885-896

2018

Volltextzugriff (PDF)

Aurora Kinases as Anticancer Drug Targets

Clinical cancer research, 2008-03, Vol.14 (6), p.1639-1648

2008

Volltextzugriff (PDF)

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.214-227

2022

Volltextzugriff (PDF)

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Journal of experimental & clinical cancer research, 2022-06, Vol.41 (1), p.186-14, Article 186

2022

Volltextzugriff (PDF)

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

The lancet oncology, 2013-08, Vol.14 (9), p.893-900

2013

Volltextzugriff (PDF)

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

BMC cancer, 2021-04, Vol.21 (1), p.441-441, Article 441

2021

Volltextzugriff (PDF)

SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)

Journal of thoracic oncology, 2015-02, Vol.10 (2), p.387-391

2015

Volltextzugriff (PDF)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer

Cancers, 2024-02, Vol.16 (5), p.940

2024

Volltextzugriff (PDF)

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3540-3546

2009

Volltextzugriff (PDF)

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Clinical lung cancer, 2014-01, Vol.15 (1), p.1-6

2014

Volltextzugriff (PDF)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in oncology, 2019-03, Vol.9, p.132-132

2019

Volltextzugriff (PDF)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002973

2021

Volltextzugriff (PDF)

Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers

Frontiers in oncology, 2024-02, Vol.14, p.1328512-1328512

2024

Volltextzugriff (PDF)

Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3296-3301

2007

Volltextzugriff (PDF)

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5788-5793

2009

Volltextzugriff (PDF)

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing

The Journal of molecular diagnostics : JMD, 2021-05, Vol.23 (5), p.507-520

2021

Volltextzugriff (PDF)

Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma

Free radical biology & medicine, 2009-06, Vol.46 (12), p.1650-1657

2009

Volltextzugriff (PDF)

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

Vaccines (Basel), 2023-05, Vol.11 (5), p.969

2023

Volltextzugriff (PDF)

Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4771-4776

2008

Volltextzugriff (PDF)

Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer

Clinical lung cancer, 2012-03, Vol.13 (2), p.90-95

2012

Volltextzugriff (PDF)

1 – 25 von 378

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(366)
Mit Volltextzugriff
(342)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(217)
Life Sciences & Biomedicine
(212)
Humans
(193)
Oncology
(117)
Male
(105)
Female
(93)
Middle Aged
(69)
Aged
(67)
Lung Neoplasms - Drug Therapy
(61)
Biological And Medical Sciences
(54)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(50)
Medical Sciences
(50)
Adult
(44)
Lung Neoplasms - Pathology
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Aged, 80 And Over
(37)
Carcinoma, Non-Small-Cell Lung - Pathology
(34)
Treatment Outcome
(34)
Lung Cancer
(31)
Tumors
(31)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Aurora Kinases as Anticancer Drug Targets

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers

Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing

Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003

Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer

Suchergebnisse filtern